Scientists say they now know what went wrong with Johnson & Johnson’s Covid vaccine
Australian researchers claim to have identified the cause of rare blood clots (VITT) associated with the Johnson & Johnson and Oxford-AstraZeneca Covid vaccines. They suggest a reaction to the adenovirus used in the vaccines, coupled with a genetic predisposition, led to the immune system confusing a viral protein with a blood protein (PF4), triggering dangerous clotting antibodies. This discovery could lead to safer future adenovirus-vector vaccines.
J&J’s baby powder caused a woman’s fatal cancer, Philly jury finds, awarding her family $250,000
A Philadelphia jury has ordered Johnson & Johnson to pay $250,000 to the family of Gayle Emerson, finding that the company's talc-based baby powder caused her ovarian cancer. Emerson, who died months after filing her complaint in 2019, was part of a nationwide wave of litigation against J&J. The verdict included $50,000 in compensatory damages and $200,000 in punitive damages, despite J&J's defense that the baby powder was not responsible and Emerson had other risk factors.
Johnson & Johnson ordered to pay $250,000 in talc powder lawsuit
A Pennsylvania state court jury has ordered Johnson & Johnson to pay $250,000 to the family of a woman who alleged their talc-based baby powder caused her ovarian cancer. The lawsuit, filed by Gayle Emerson in 2019, claimed the company failed to warn consumers despite knowing the dangers. The jury awarded $50,000 in compensatory damages and $200,000 in punitive damages to her family.
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
A Pennsylvania jury has found Johnson & Johnson liable for contributing to a woman's ovarian cancer, awarding her family $250,000. The case centered on claims that J&J knew its talc-based baby powder was dangerous but failed to warn consumers. This verdict follows other recent judgments against the company as it faces thousands of lawsuits alleging its talc products caused various cancers.
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
A Pennsylvania jury has awarded $250,000 to the family of Gayle Emerson, who claimed Johnson & Johnson's talc-based baby powder caused her ovarian cancer. This verdict marks a win for plaintiffs in the ongoing nationwide talc litigation against J&J, which faces over 67,000 lawsuits alleging its products caused cancer. The company maintains its products are safe, but has a mixed record in previous talc trials and multiple attempts to resolve the litigation through bankruptcy have been rejected.
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
A Pennsylvania jury has found Johnson & Johnson liable for causing ovarian cancer in a woman who used its talc-based baby powder, awarding her family $250,000. J&J faces over 67,000 similar lawsuits, with claims that its talc products contained asbestos and caused various cancers. This verdict follows J&J's repeated attempts to resolve the litigation through bankruptcy, all of which have been rejected by federal courts.
Johnson And Johnson Faces Legal Risks While Cardiac Data Supports Valuation
Johnson & Johnson (JNJ) is navigating significant developments including a talc lawsuit verdict, new research on rare blood clots associated with its COVID vaccine, and positive pilot data for its cardiac catheter platforms. The stock has shown strong performance, but investors are advised to consider both legal and scientific risks alongside the potential from new medical devices.
Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy
Takeda Pharmaceutical Company (TAK) is advancing a Phase 3 study evaluating vortioxetine (Trintellix) in Japanese teenagers with major depressive disorder. The randomized, double-blind, placebo-controlled trial aims to assess the efficacy and safety of once-daily oral vortioxetine against a placebo over 14 weeks. This sustained focus on neuroscience disorders, specifically in the underserved pediatric mental health segment, aligns with Takeda's broader strategy to expand its pipeline beyond its core franchises, potentially opening up new revenue streams in the future.
Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K
A Pennsylvania state court jury ordered Johnson & Johnson to pay $250,000 to the family of Gayle Emerson, finding the company liable for her ovarian cancer which her family argued resulted from her use of J&J's talc-based baby powder. The verdict included $50,000 in compensatory damages and $200,000 in punitive damages. This ruling follows previous attempts by J&J to resolve talc litigation through bankruptcy, which have been rejected by federal courts.
CVRx highlights revenue growth in Q4, increased momentum going forward
CVRx reported $16 million in revenue for Q4 2025, a 4% increase year-over-year, with total 2025 revenue reaching $56.7 million, up 10% from 2024. The company is heading into 2026 with increased momentum due to new Category 1 CPT codes for its Barostim device and the initiation of a new clinical trial, BENEFIT-HF, aiming to expand eligibility for heart failure therapy. CVRx's CEO, Kevin Hykes, expressed confidence that these developments will support accelerated growth and make Barostim therapy more accessible.
Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study
Johnson & Johnson announced 100% acute procedural success with no adverse events in the 12-month pilot phase of its OMNY-AF study, which investigates the OMNYPULSE Platform for treating symptomatic paroxysmal atrial fibrillation. This positive data was shared at the 31st Annual AF Symposium. Concurrently, RBC Capital raised J&J's price target to $255 from $240, reiterating an Outperform rating, despite ongoing talc litigation concerns, citing the company's strong financial position.
Pfizer Hemophilia And Obesity Updates Add Context To Valuation Debate
Pfizer has made progress in its late-stage pipeline with FDA Priority Review granted for HYMPAVZI, a hemophilia treatment, and positive Phase 2b data for PF-3944, an obesity treatment. These developments provide important context for Pfizer's valuation, especially as the company navigates post-patent expiration challenges. Despite these positive updates, the article notes forecast earnings decline and an unsustainable dividend, suggesting pipeline progress alone may not entirely offset fundamental pressures.
US withdraws newly updated list of firms allegedly aiding China's military
The U.S. government temporarily published and then withdrew an updated list of Chinese firms accused of aiding Beijing's military, which controversially added major tech companies like Alibaba and Baidu while removing top memory chipmakers CXMT and YMTC. The short-lived publication and subsequent withdrawal have sparked debate among China hawks and reflect the Trump administration's complex approach to U.S.-China relations, particularly as a trade truce is in effect. Although inclusion on the Pentagon list doesn't immediately impose sanctions, it signals U.S. military concerns and could affect future contracting.
Shariaportfolio Inc. Has $3.27 Million Stock Position in Johnson & Johnson $JNJ
Shariaportfolio Inc. significantly increased its stake in Johnson & Johnson (JNJ) by 47.9% in Q3, now owning 17,617 shares valued at $3.27 million, making it their 14th largest holding. Several other institutional investors also adjusted their positions in JNJ during the same period. Johnson & Johnson recently reported quarterly earnings, announced a $1.30 dividend, and has received a consensus "Moderate Buy" rating from analysts with a target price of $233.73.
Metis Global Partners LLC Has $25.15 Million Holdings in Johnson & Johnson $JNJ
Metis Global Partners LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 5.4% in the third quarter, but still holds 135,633 shares valued at $25.15 million, making it their 24th largest holding. Other institutional investors like Brighton Jones LLC, United Bank, and Sivia Capital Partners LLC increased their positions in JNJ. The article also provides details on JNJ's stock performance, recent earnings, dividend announcement, and current analyst ratings.
Public Sector Pension Investment Board Has $53.09 Million Holdings in Johnson & Johnson $JNJ
Public Sector Pension Investment Board significantly reduced its stake in Johnson & Johnson (NYSE:JNJ) by 49.4% in the third quarter, holding 286,327 shares valued at $53.09 million. Despite this, other hedge funds increased or initiated positions in JNJ, and institutional investors collectively own 69.55% of the company's stock. JNJ recently declared a quarterly dividend and analysts maintain a "Moderate Buy" rating with a consensus target price of $233.73.
Does Johnson & Johnson Stock Still Have Room to Run?
Johnson & Johnson (JNJ) stock shows strong momentum due to its high-margin Innovative Medicine portfolio, which is driving growth despite revenue headwinds from Stelara biosimilar erosion. While the company exhibits strong fundamentals like high operating cash flow and margin, the key investment debate revolves around whether new pipeline growth can fully offset patent cliffs and litigation risks. JNJ's stock is currently trading at its 52-week high, raising questions about its future growth potential.
Coherus Oncology prices $50.1 million public offering of common stock
Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share, aiming to generate approximately $50.1 million in gross proceeds. The company plans to use these proceeds for the commercialization of LOQTORZI, continued clinical development of product candidates, and general corporate purposes. This follows other recent news, including a clinical supply agreement with Johnson & Johnson and Oppenheimer reiterating an Outperform rating on Coherus stock.
Ascentage China IND Clearance Puts BTK Degrader On Global Cancer Track
Ascentage Pharma Group International has received investigational new drug clearance in China for APG-3288, its next-generation BTK targeted protein degrader, following earlier U.S. FDA approval. This dual clearance positions the program on a global path, enhancing its potential for treating resistant blood cancers. Investors should monitor initial safety data and clinical trial progress to assess its market impact and role in Ascentage's pipeline, especially given the established clinical problem of resistance to current BTK inhibitors.
Vertex Expands Beyond Cystic Fibrosis With WuXi Autoimmune Alliance
Vertex Pharmaceuticals has entered an exclusive license and collaboration with WuXi Biologics to develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases, expanding Vertex's pipeline beyond cystic fibrosis and gene editing. This partnership broadens Vertex's focus into a new immunology area, leveraging its cystic fibrosis cash flows to access external science and scale financial exposure with progress. While preclinical autoimmune programs carry high risk, the deal could add a new growth driver and help Vertex build a broader autoimmune portfolio.
Municipal Employees Dumps 528,000 RING Shares for $35.7 Million
The Municipal Employees' Retirement System of Michigan sold 528,148 shares of iShares MSCI Global Gold Miners ETF (RING) during Q4 2025, valued at $35.65 million. Despite this reduction, the fund still holds 844,062 shares, indicating continued bullish sentiment on the gold mining sector after a significant price appreciation in gold and gold mining stocks.
Pentair Just Paid Out: Is This Industrial Dividend Built to Last?
Pentair (PNR) recently distributed its 50th consecutive annual dividend increase, with an 8.0% raise in 2026, surpassing larger dividend aristocrats like Johnson & Johnson and Procter & Gamble. Despite a modest 1.01% yield, Pentair's dividend is highly sustainable, supported by an exceptionally low 20.2% payout ratio and free cash flow covering dividends 4.55 times. Wall Street analysts currently rate PNR as a "Buy" with an 11.4% upside, suggesting it is a "Growth Aristocrat" for long-term investors seeking both income growth and capital appreciation.
Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?
Abbott Laboratories recently increased its quarterly dividend, reaching 13 consecutive years of dividend growth, maintaining its Dividend Aristocrat status. While strong in medical devices and innovation, the company faces challenges including a Class I recall for its FreeStyle Libre and weakness in its nutrition segment. Despite these headwinds and a moderately high payout ratio, Abbott's management remains committed to dividend growth, supported by adequate cash flow and strategic acquisitions.
10 Best Medical Research Stocks to Buy According to Hedge Funds
This article identifies Amgen Inc. (NASDAQ:AMGN) as one of the best medical research stocks favored by hedge funds. It details Amgen's strong fiscal Q4 and full-year 2025 financial performance, including double-digit revenue and EPS growth, and highlights analyst ratings. The company, a biotechnology firm specializing in human therapeutics for complex cancers, also provided a positive revenue outlook for 2026.
Johnson & Johnson $JNJ Shares Bought by Varma Mutual Pension Insurance Co
Varma Mutual Pension Insurance Co increased its stake in Johnson & Johnson (JNJ) by 8.9% in the third quarter, now holding 378,256 shares valued at approximately $70.14 million. This makes J&J the 29th-largest position in Varma's portfolio, representing about 0.5% of its total holdings. Johnson & Johnson recently reported strong quarterly earnings, declared a dividend, and maintains a "Moderate Buy" consensus rating from analysts with a target price of $233.73.
Big Health Raises $23.7M from .406 Ventures, AlleyCorp, CVS Ventures, Blue Venture Fund
Digital therapeutics provider Big Health has successfully raised $23.7 million in a funding round led by .406 Ventures and AlleyCorp, with participation from CVS Health Ventures and Blue Venture Fund. The capital will primarily be used to accelerate the commercialization of its FDA-cleared digital therapeutics, SleepioRx for insomnia and DaylightRx for generalized anxiety disorder. CEO Yael Berman notes improved reimbursement pathways and provider receptiveness are creating a more favorable market for digital mental health solutions, despite past challenges faced by other companies in the space.
Johnson & Johnson $JNJ Shares Sold by LSV Asset Management
LSV Asset Management reduced its stake in Johnson & Johnson ($JNJ) by 2.6% in the third quarter, selling 80,954 shares, though JNJ remains its sixth-largest holding. Despite this, other institutional investors like Clark Asset Management and AustralianSuper significantly increased their positions, raising overall institutional ownership to about 69.55%. Johnson & Johnson also declared a quarterly dividend of $1.30 per share, with recent analyst ratings showing a "Moderate Buy" consensus.
Cue Biopharma Names Lucinda Warren Chief Financial Officer
Cue Biopharma has appointed Lucinda Warren as Chief Financial and Business Officer, consolidating the company's finance and business functions under her leadership. Warren, who has over 30 years of experience in the pharmaceutical and biotechnology sectors, will maintain her existing compensation and employment terms. The company's stock (CUE) currently holds a Hold rating with a $0.29 price target, and TipRanks' AI Analyst assesses it as Neutral due to weak financial performance and bearish technicals, partially offset by corporate events extending cash runway and potential partnerships.
Drake & Associates LLC Sells 7,105 Shares of Johnson & Johnson $JNJ
Drake & Associates LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 32.7% in Q3, selling 7,105 shares, leaving them with 14,653 shares valued at $2.725 million. Despite this, Wall Street analysts maintain a "Moderate Buy" rating for JNJ, with an average target price of $233.73, and recent earnings reported $2.46 EPS and $24.28 billion in revenue. The company also declared a quarterly dividend of $1.30 per share, payable on March 10th.
Caisse Des Depots ET Consignations Sells 21,113 Shares of Bristol Myers Squibb Company $BMY
Caisse Des Depots ET Consignations reduced its stake in Bristol Myers Squibb by 36.7% in the third quarter, selling 21,113 shares and now holding 36,374 shares worth approximately $1.64 million. Despite this, other major investors like Vanguard, Charles Schwab, and Geode increased their positions, and Norges Bank initiated a significant stake, bringing institutional and hedge fund ownership to about 76.41%. Bristol Myers Squibb recently reported mixed earnings, missing EPS estimates but slightly beating revenue, while also raising its quarterly dividend and providing FY2026 EPS guidance.
Mouthrinse Market Is Going to Boom | Colgate-Palmolive • Procter & Gamble • Johnson & Johnson • GlaxoSmithKline
Coherent Market Insights has released a comprehensive report on the Mouthrinse Market, detailing industry trends, growth opportunities, market share, and forecasts from 2026-2033. The report analyzes competitive landscapes, geographic distribution, and growth potential, covering industry performance, risk assessment, and economic analysis. Key players include Colgate-Palmolive, Procter & Gamble, and Johnson & Johnson, with segmentation across therapeutic, cosmetic, alcohol-based, and natural mouthrinses.
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns
Rothschild Redburn downgraded Legend Biotech Corp. (NASDAQ:LEGN) from Buy to Neutral and significantly cut its price target to $24.00 from $83.00, citing increased competition for its multiple myeloma drug, Carvykti. This decision follows insights from the ASH 2025 conference which suggested a strong physician inclination towards bispecific-based therapies over Carvykti, leading to a substantial reduction in global peak sales estimates for the drug. Other analysts have also responded with mixed ratings and price targets following recent sales figures and regulatory developments.
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy
H.C. Wainwright has increased its price target for Protagonist Therapeutics, Inc. (PTGX) to $117 from $80, maintaining a Buy rating. The firm based its decision on the company's strong drug development track record and the potential of its pipeline assets, including PN-8047 and obesity programs. Protagonist Therapeutics also anticipates multiple Phase 2 and Phase 3 readouts in immunology, hematology, and obesity, supported by existing partnerships.
Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal
Madrigal Pharmaceuticals has signed a second licensing deal with a Chinese biotech, Suzhou Ribo Life Science Co., Ltd., to expand its pipeline of treatments for MASH (Metabolic Dysfunction-Associated Steatohepatitis). This agreement follows a previous deal, indicating Madrigal's strategic focus on building out its MASH portfolio through collaborations. The article highlights Madrigal's efforts to strengthen its position in the MASH therapeutic area.
Scientists Figured Out the Problem With Johnson & Johnson’s COVID Vaccine
Researchers have identified the cause of rare but dangerous blood clotting associated with the Johnson & Johnson and AstraZeneca COVID-19 vaccines, known as VITT. The study, published in The New England Journal of Medicine, shows that VITT is an immune overreaction to the adenovirus used in the vaccines, occurring in individuals with specific genetic predispositions. This discovery could lead to safer vaccine designs and bolster public trust in vaccine development.
The Bull Case For Cytokinetics (CYTK) Could Change Following MYQORZO Progress And HCM Advocacy Grants
Cytokinetics recently announced the approval of MYQORZO (aficamten) for symptomatic obstructive HCM and its marketing review status in the EU, alongside awarding grants to hypertrophic cardiomyopathy patient advocacy groups. This move ties the company's commercial goals to disease awareness and patient engagement. The article examines how MYQORZO's regulatory progress and HCM-focused advocacy grants will influence Cytokinetics' investment narrative and future risk profile, emphasizing the importance of successful commercial execution and managing costs for the company's growth.
Should You Buy ISRG Stock Despite a 13% Fall in Three Months?
Intuitive Surgical (ISRG) stock has fallen 13.5% in the last three months despite strong procedure growth and adoption of its da Vinci 5 system. The company's fundamentals, including projected 13-15% global da Vinci procedure growth in 2026 and expansion into new surgical categories, suggest a constructive investment stance. While facing margin headwinds and competitive pressures, ISRG's market leadership and recurring revenue base position it for continued value creation, leading to a Zacks Rank #1 (Strong Buy).
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy
H.C. Wainwright has increased its price target for Protagonist Therapeutics, Inc. (PTGX) to $117 from $80, reiterating a "Buy" rating. This decision is based on the company's strong drug development track record and the potential of its pipeline assets, including PN-8047 and obesity programs. Protagonist Therapeutics is advancing multiple late-stage assets and maintains partnerships with Johnson & Johnson and Takeda, providing non-dilutive funding.
Idaho joins $17.85M settlement over alleged generic drug price-fixing
Idaho Attorney General Raúl Labrador announced that Idaho has joined 48 other states and territories in a $17.85 million settlement with pharmaceutical companies Lannett Company, Inc. and Bausch Health US, LLC over alleged generic drug price-fixing. The settlement resolves accusations that the companies inflated prices and limited competition for generic prescription drugs. Idaho residents and businesses who purchased certain generic prescription drugs between May 2009 and December 2019 may be eligible for compensation.
Stratos Wealth Advisors LLC Boosts Holdings in Johnson & Johnson $JNJ
Stratos Wealth Advisors LLC significantly increased its stake in Johnson & Johnson (JNJ) by 257% in the third quarter, now owning 45,907 shares worth $8.51 million. Institutional investors collectively hold about 69.55% of JNJ stock. Johnson & Johnson recently met earnings estimates with $2.46 EPS and reported revenue of $24.56 billion, while analysts maintain a "Moderate Buy" rating with an average price target of $233.73.
Vertex Expands Beyond Cystic Fibrosis With WuXi Autoimmune T Cell Deal
Vertex Pharmaceuticals has signed an exclusive global agreement with WuXi Biologics to develop a preclinical trispecific T-cell engager for B-cell mediated autoimmune diseases, marking a strategic expansion beyond its cystic fibrosis treatments. This move introduces a new modality and disease focus to Vertex's portfolio, leveraging WuXi's expertise to scale T-cell engager development. While presenting high technical and regulatory risks for a preclinical asset, successful development could diversify Vertex's revenue streams and reduce its reliance on cystic fibrosis therapies.
ING Groep NV Buys 132,234 Shares of Eli Lilly and Company $LLY
ING Groep NV significantly increased its stake in Eli Lilly and Company (LLY) by 419.9% in Q3, purchasing an additional 132,234 shares to bring its total to 163,723 shares valued at approximately $124.92 million. This move positions LLY as ING Groep NV's 29th largest holding. Eli Lilly has reported strong financial results, beating earnings expectations with $7.54 EPS and $19.29 billion in revenue, and has issued optimistic 2026 guidance while raising its quarterly dividend.
80,393 Shares in Johnson & Johnson $JNJ Acquired by Caprock Group LLC
Caprock Group LLC recently acquired 80,393 shares of Johnson & Johnson (NYSE:JNJ) totaling approximately $14.35 million. This acquisition is part of a broader trend of institutional investors adjusting their stakes in the company, with various firms like AustralianSuper Pty Ltd and Guinness Asset Management LTD also increasing their holdings. Johnson & Johnson continues to receive a "Moderate Buy" consensus rating from analysts, with a price target of $233.73, and recently announced a quarterly dividend of $1.30 per share.
ING Groep NV Buys 266,299 Shares of Johnson & Johnson $JNJ
ING Groep NV significantly increased its stake in Johnson & Johnson ($JNJ) by purchasing an additional 266,299 shares in the third quarter, bringing its total holdings to 959,228 shares worth $177.86 million. Other institutional investors also adjusted their positions in JNJ, which currently holds a "Moderate Buy" consensus rating from analysts with a target price of $233.73. Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, payable on March 10th.
Philadelphia Jury Urged to ‘Send a Message’ to Johnson & Johnson in Second Talc Trial
A Philadelphia jury heard closing arguments in a talc mass tort trial against Johnson & Johnson, with attorneys for the estate of Gayle Emerson urging the jury to hold the company accountable and award significant punitive damages based on its substantial net worth. Defense attorneys for Johnson & Johnson maintained that their baby powder did not cause Emerson’s cancer, citing other contributing factors, while highlighting previous defense victories for the company in similar cases after years of legal proceedings.
Is Pfizer Stock Heading for a Fall?
This article analyzes potential risks for Pfizer (PFE) stock, including escalating liability from Depo-Provera litigation, deteriorating working capital, and margin erosion due to patent cliffs and underperforming acquisitions. It highlights the company's financial performance metrics and historical stock dips during market shocks, suggesting that despite its size, Pfizer is not immune to significant downturns. The Trefis analysis provides a price target with an upside, but also outlines the critical threats that could impact its future stock performance.
Is Johnson & Johnson Still a Worthy Investment in 2026?
Johnson & Johnson (JNJ) has seen its stock rise by 53% over the past year, outperforming many tech giants due to its stability. Despite facing challenges like drug price negotiations, patent cliffs, and ongoing lawsuits, the company demonstrates resilience through its diverse drug portfolio and strong financial health. JNJ remains attractive to long-term income investors due to its consistent dividend growth and sound financial position, making it a worthy investment in 2026.
With Becton Dickinson Stock Sliding, Have You Assessed The Risk?
Becton Dickinson (BDX) stock has fallen 17.2% due to renewed concerns about lowered FY2026 profit guidance following a spin-off. The article examines the stock's resilience during past economic downturns, noting its performance was often slightly worse than the S&P 500 but with varying recovery times. It suggests investors consider a diversified portfolio approach instead of solely focusing on individual stock movements.
Statutory Profit Doesn't Reflect How Good GSK's (LON:GSK) Earnings Are
GSK's recent stock performance aligns with strong earnings, yet the statutory profit may not fully capture its potential due to a UK£1.5 billion reduction from unusual, likely one-off items. These unusual items suggest that future profits could be higher if they don't recur, indicating that GSK's reported profit might actually understate its true earnings capability. The company has also shown impressive earnings per share growth over the last year.
Iradimed Stock Surges as Record Quarterly Revenue Streak Hits 18
Iradimed Corporation (IRMD) shares surged by 9.26% after reporting its 18th consecutive quarter of record revenue, reaching $22.7 million in Q4 2025 – a 17% increase year-over-year. Non-GAAP net income also grew by 23% to $7.0 million, or $0.54 per share, surpassing analyst expectations. The company also announced an increased quarterly dividend and provided optimistic revenue guidance for 2026, projecting $91 million to $96 million.
